Table 1.
Demographics of subjects receiving either LAIV or TIV
| Parameters | Group 1 | Group 2 | Group 3 | Groups Combined | ||||
|---|---|---|---|---|---|---|---|---|
| LAIV | TIV | LAIV | TIV | LAIV | TIV | LAIV | TIV | |
| Number | 45 | 44 | 50 | 48 | 27 | 29 | 122 | 121 |
| Gender | ||||||||
| Male | 23 (51%) | 26 (59%) | 25 (50%) | 28 (58%) | 17 (63%) | 10 (34%) | 65 (53%) | 64 (53%) |
| Female | 22 (49%) | 18 (41%) | 25 (50%) | 20 (42%) | 10 (37%) | 19 (66%) | 57 (47%) | 57 (47%) |
| Ethnicity | ||||||||
| White1 | 5 (11%) | 4 (9%) | 7 (14%) | 4 (8%) | 7 (26%) | 3 (10%) | 20 (16%) | 11 (9%) |
| Black1 | 32 (71%) | 33 (75%) | 29 (58%) | 32 (67%) | 11 (41%) | 17 (59%) | 72 (59%) | 82 (68%) |
| Hispanic | 8 (18%) | 6 (14%) | 13 (26%) | 12 (25%) | 7 (26%) | 8 (28%) | 27 (22%) | 26 (21%) |
| Others | 0 (0%) | 1 (2%) | 1 (2%) | 0 | 2 (7%) | 1 (3%) | 3 (2%) | 2 (2%) |
| Age - years mean (STD) | 13.0 (2.7) | 12.2 (3.0) | 10.8 (3.2) | 12.2 (3.0) | 9.6 (3.1) | 10.9 (2.9) | 11.4 (3.3) | 11.9 (3.0) |
| Entry CD4% mean (STD) | 30.7 (8.9) | 31.9 (7.5) | 32.9 (8.1) | 32.6 (7.8) | 38.0 (5.9) | 39.9 (6.7) | 33.2 (8.4) | 34.1 (8.1) |
| Entry CD4 count mean (STD) | 732 (328) | 825 (373) | 842 (344) | 846 (362) | 1023 (346) | 1089 (349) | 842 (353) | 897 (376) |
| Entry Viral Load (Log10)* (STD) | 2.8 (0.6) | 2.7 (0.8) | 2.7 (0.7) | 2.7 (0.7) | 2.6 (0.7) | 2.7 (0.6) | 2.7 (0.7) | 2.7 (0.7) |
1
non-Hispanic
*
Roche Amplicor Monitor HIV RT PCR was used for 179 subjects (if copies/ml<400, then copies/ml was set to 400); Roche UltraSensitive HIV RT PCR was used for 62 subjects (if copies/ml <50, then copies/ml was set to <500); OTC NASBA HIV RNA QT assay was used for 2 subjects (if copies/ml <500, then copies/ml was set to 500).